| Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964) |
|---|
| 06/10/2004 | WO2004048512A2 Novel proteins and nucleic acids encoding same |
| 06/10/2004 | WO2004048325A2 Modulation of jagged 1 expression |
| 06/10/2004 | WO2004047872A2 Treatment of neurodegenerative disease through intracranial delivery of short interfering rna (sirna) |
| 06/10/2004 | WO2004047856A1 Cancer metastasis inhibitor |
| 06/10/2004 | WO2004047855A2 Proteins involved in the regulation of energy homeostasis |
| 06/10/2004 | WO2004047812A1 Hollow nanoparticles of protein and drug using the same |
| 06/10/2004 | WO2004047770A2 Cytotherapeutics, cytotherapeutic units and methods for treatments using them |
| 06/10/2004 | WO2004047767A2 Methods for identifying risk of breast cancer and treatments thereof |
| 06/10/2004 | WO2004047764A2 Modulation of hiv replication by rna interference |
| 06/10/2004 | WO2004047762A2 Methods for treating cancer using porimin as a target |
| 06/10/2004 | WO2004047758A2 Methods of therapy and diagnosis using targeting of cells that express p2y10 |
| 06/10/2004 | WO2004047741A2 Modulation of iap-like expression |
| 06/10/2004 | WO2004047740A2 Composition and method for treating lupus nephritis |
| 06/10/2004 | WO2004047736A2 Modulation of bcl2-associated athanogene expression |
| 06/10/2004 | WO2004047734A2 Methods and immune modulatory nucleic acid compositions for preventing and treating disease |
| 06/10/2004 | WO2004047727A2 Compositions and methods for diagnosing and treating mood disorders |
| 06/10/2004 | WO2004047720A2 Methods of inhibiting angiogensis via modification of a lysyl oxidase |
| 06/10/2004 | WO2004047623A2 Methods for identifying risk of breast cancer and treatments thereof |
| 06/10/2004 | WO2004047514A2 Methods for identifying risk of breast cancer and treatments thereof |
| 06/10/2004 | WO2004037202A9 Gb virus c and methods of treating viral infections |
| 06/10/2004 | WO2004034995A9 Methods and reagents for inducing immunity |
| 06/10/2004 | WO2004030660A3 Compositions for treatment of prostate and other cancers |
| 06/10/2004 | WO2004029278A3 Aav itr-mediated modulation |
| 06/10/2004 | WO2004005488A3 Replacing liver cells with bone marrow-derived cells for treating disease and expressing therapeutic genes |
| 06/10/2004 | WO2004003145A3 Compositions and methods for modulating physiology of epithelial junctional adhesion molecules for enhanced mucosal delivery of therapeutic compounds |
| 06/10/2004 | WO2003106476A8 Nucleic acid mediated inhibition of enterococcus infection and cytolysin toxin activity |
| 06/10/2004 | WO2003104470A3 Retrons for gene targeting |
| 06/10/2004 | WO2003102140A3 Cftr modifier genes and expressed polypeptides useful in treating cystic fibrosis |
| 06/10/2004 | WO2003099224A3 Antisense moodulation of kinesin-like 1 expression |
| 06/10/2004 | WO2003089571A3 Ehrlichia canis genes and vaccines |
| 06/10/2004 | WO2003087323A3 Biologic modulations with nanoparticles |
| 06/10/2004 | WO2003087158A3 Regulation of human transient receptor potential channel |
| 06/10/2004 | WO2003083039A8 Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
| 06/10/2004 | WO2003070970A3 RNA INTERFERENCE MEDIATED INHIBITION OF NF-KAPPA B/REL-A GENE EXPRESSION USING SHORT INTERFEREING NUCLEIC ACID (siNA) |
| 06/10/2004 | WO2003064626A3 Double-stranded oligonucleotides |
| 06/10/2004 | WO2003062469A3 Gene matn3 or matrilin-3 linked to osteoarthritis treatment |
| 06/10/2004 | WO2003040170A9 Antibodies to cd40 |
| 06/10/2004 | WO2003039346A9 Diagnostics and therapeutics for ocular abnormalities |
| 06/10/2004 | WO2003037258A3 Methods and compositions for the treatment and diagnosis of pain disorders using 2047 |
| 06/10/2004 | WO2003015711A3 Combination motif immune stimulatory oligonucleotides with improved activity |
| 06/10/2004 | WO2003012082A3 Method for modulating stem cell differentiation using stem loop rna |
| 06/10/2004 | WO2003007800A9 Methods for diagnosing and treating diseases and conditions of the digestive system and cancer |
| 06/10/2004 | WO2002090600A3 A method for regulating immune function in primates using the foxp3 protein |
| 06/10/2004 | WO2002057293B1 Modified zinc finger binding proteins |
| 06/10/2004 | WO2002040629A3 Promoters exhibiting endothelial cell specificity and methods of using same |
| 06/10/2004 | US20040110935 Universal carrier for targeting molecules to Gb3 receptor expressing cells |
| 06/10/2004 | US20040110928 Peptide conjugates for drug delivery |
| 06/10/2004 | US20040110920 Novel g protein-coupled receptor protein and dna thereof |
| 06/10/2004 | US20040110716 Cancer gene therapy based on translational control of a suicide gene |
| 06/10/2004 | US20040110715 Differs from nucleotide sequence of wild-type IFN alpha -17 gene, in that it comprises one or several SNPs (Single Nucleotide Polymorphism[s]); anticarcinogenic and antiproliferative agents; side effect reduction |
| 06/10/2004 | US20040110714 Stabilized naked DNA compositions |
| 06/10/2004 | US20040110712 Methods for treating patients and identifying therapeutics |
| 06/10/2004 | US20040110710 Methods of reducing ischemic injury |
| 06/10/2004 | US20040110709 Genetic modification of the lung as a portal for gene delivery |
| 06/10/2004 | US20040110708 Binary hybrid mutational vectors |
| 06/10/2004 | US20040110707 Method of treating neurological diseases |
| 06/10/2004 | US20040110706 Nucleic acid with point mutations, deletions, insertions and/or rearrangements ; hyperthermia, myasthenia, ataxia, neuropathic and inflammatory pain; Alzheimer*s, Parkinson's disease; schizophrenia, hyperekplexia, myotonias and arrhythmia |
| 06/10/2004 | US20040110705 Antisense oligonucleotides targeted to nucleic acids encoding Talin, a cytoplasmic protein; gene expression inhibition |
| 06/10/2004 | US20040110703 Gene expression inhibition; molecular hybridization; drug screening, medical diagnosis |
| 06/10/2004 | US20040110702 Nucleotide hybridizes with nucleic acid encoding MAGE-D1(melanoma antigen); gene expression inhibition |
| 06/10/2004 | US20040110697 Nucleic acid injected into hapatic vein lumen and delivered to primate liver |
| 06/10/2004 | US20040110696 Gene therapy system and method using alpha-msh and its derivatives |
| 06/10/2004 | US20040110695 Phospholipid vesicle having exogenous antigen orpolynucleic acid coding for antigen; adapted to be phagocytosed by antigen presenting cells |
| 06/10/2004 | US20040110690 Transporter peptide capable of translocating across biological membrane of pancreatic B-cells, hepatocytes, colon cells, muscle cells and/or lung cells; drug delivery; biochemical conjugation |
| 06/10/2004 | US20040110684 Genetically engineered caveolin-; antiischemic, antitumor, and wound healing agents; cardiovascular and brain disorders |
| 06/10/2004 | US20040110682 Nucleic acid construct for expressing active substances which can be activated by proteases, and preparation and use |
| 06/10/2004 | US20040110677 Stimulating differentiation in growth of osteoblasts and osteoclasts; wound healing of bone fractures and de novo bone formation; osteoporosis; bone cancer treatment; polynucleotide encoding polypeptide; genetic engineering |
| 06/10/2004 | US20040110676 Administering huntington protein or biologically-active fragment or variant to treat Huntington's, Alzheimer's , Parkinson's , amyotrophic lateral sclerosis, multiple sclerosis, and other neurodegenerative diseases |
| 06/10/2004 | US20040110674 Nucleic acid and corresponding protein entitled 205p1b5 useful in treatment and detection of cancer |
| 06/10/2004 | US20040110673 Treatment of diseases such as diabetes with administering CD83 and T-cells for medical diagnosis and proteins |
| 06/10/2004 | US20040110669 Destruction of prions using vibriolysin or variants thereof |
| 06/10/2004 | US20040110668 Nucleic acid sequences differentially expressed in cancer tissue |
| 06/10/2004 | US20040110289 Obtaining liver cells suspension via proteolytic digestion followed by density gradient centrifugation; liver regeneration and transplantation therapy |
| 06/10/2004 | US20040110269 Protection against mycobacterial infections |
| 06/10/2004 | US20040110263 Glycosylphosphatidylinositol specific phospholipase d proteins for the treatment or diagnosis of atherosclerosis |
| 06/10/2004 | US20040110259 Drug metabolizing enzymes |
| 06/10/2004 | US20040110235 for the treatment of diabetes and other diseases using systematic evolution of ligands by exponential enrichment (SELEX) |
| 06/10/2004 | US20040110218 BMOG, a novel protein member of the myelin-oligodendrocyte glycoprotein family and its use for immunomodulatory purposes |
| 06/10/2004 | US20040110181 Novel streptococcus pneumoniae open reading frames encoding polypeptide antigens and uses thereof |
| 06/10/2004 | US20040110168 Diagnostics and therapeutics for osteoporosis |
| 06/10/2004 | US20040110155 Modulation of SLC26A2 expression |
| 06/10/2004 | US20040110152 Antisense oligonucleotides for controlling expression of zinc-dependent endopeptidase and for treatment of hyperproliferative disorders |
| 06/10/2004 | US20040110127 Screening methods for identifying compounds which decrease HIV entry into a cell |
| 06/10/2004 | US20040109873 Genetic engineering equine herpes virus; genes coding protein |
| 06/10/2004 | US20040109861 Isolated protein complexes; screening analyzing; human t-cell leukemia virus |
| 06/10/2004 | US20040109849 Dna vaccines expressing hypervariable vh-cdr3 idiotipic determinants |
| 06/10/2004 | US20040109847 Treatment and prophylaxis with 4-1BB-binding agents |
| 06/10/2004 | US20040109844 Methods of treating age-related defects and diseases |
| 06/10/2004 | US20040109843 Pharmaceutical composition containing decoy and use of the same |
| 06/10/2004 | CA2854831A1 Treatment of mammalian reaction to ige interactions |
| 06/10/2004 | CA2796924A1 Ena nucleic acid pharmaceuticals capable of modifying splicing of mrna precursors |
| 06/10/2004 | CA2507606A1 Treatment of neurodegenerative disease through intracranial delivery of short interfering rna (sirna) |
| 06/10/2004 | CA2507249A1 Methods and immune modulatory nucleic acid compositions for preventing and treating disease |
| 06/10/2004 | CA2507215A1 Methods for treating cancer using porimin as a target |
| 06/10/2004 | CA2507125A1 Ena nucleic acid pharmaceuticals capable of modifying splicing of mrna precursors |
| 06/10/2004 | CA2507115A1 Treatment of mammalian reaction to ige interactions |
| 06/10/2004 | CA2506798A1 Compositions and systems for the regulation of genes |
| 06/10/2004 | CA2505784A1 Methods for identifying risk of breast cancer and treatments thereof |
| 06/10/2004 | CA2505534A1 Cytotherapeutics, cytotherapeutic units and methods for treatments using them |
| 06/10/2004 | CA2504561A1 Composition and method for treating lupus nephritis |